| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 11
| Issue : 2 | Page : 162-168 |
|
|
Pulmonary Rehabilitation Reduces the Sarcopenia Phenotype in Patients with Chronic Obstructive Pulmonary Disease
Abdulla Altamimi1, Aesha Shuaeeb1, Ahmed Yakout1, Dana Hassouna1, Huda Srouji1, Maha AlQaydi1, Mona Mohammed Mahmoud1, Noor Alkindi1, Qamar Kashmoola1, Ragad Alkhatib1, Rand Soudan1, Roaa Abu Tawileh1, Tahir Muhammad2, Rizwan Qaisar1
1 Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates, United Arab Emirates
2 Department of Biochemistry, Gomal Medical College, Gomal University, Dera Ismail Khan, Pakistan
Correspondence Address:
Dr. Rizwan Qaisar
Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah
United Arab Emirates
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ijrc.ijrc_20_22
|
|
|
Purpose: Sarcopenia or age-associated muscle decline is common in patients with chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation (PR) is an effective tool in reducing COPD phenotype, but its effects on sarcopenia and functional capacity are poorly known. We aimed to assess the restorative potential of PR on skeletal muscle and physical capacity in COPD patients. Methods: We investigated the male COPD patients, 56–71 years old (n = 55), through clinical examination, laboratory investigation, and spirometry. All patients were evaluated at two time points, 1 year apart before and following the PR. Reduced handgrip strength (HGS), appendicular skeletal mass index (ASMI), and gait speed were considered the clinical indexes of Sarcopenia. Enzyme-linked immunosorbent assay were used to measure the circulating markers of inflammation (C-reactive protein [CRP]) and oxidative stress (8-isoprostanes). Results: At baseline, the COPD patients had low HGS and gait speed and elevated CRP and 8-isoprostanes levels. According to four internationally recognized criteria, these patients also had a high incidence of Sarcopenia. One year of PR partially restored the HGS, gait speed, CRP, and 8-isoprostanes levels (all P < 0.05). However, the ASMI values were insignificantly restored following PR. PR also reduced the incidence of sarcopenia in COPD patients. Among various criteria for sarcopenia, the international working group on sarcopenia yielded the highest incidence of sarcopenia in COPD patients. Conclusion: Altogether, our data show the therapeutic potential of PR in skeletal muscle, physical performance, and systemic health in patients with COPD.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
